CLDN22: A Drug Target / Disease Biomarker (G53842)

Target Name: CLDN22

NCBI ID: G53842

CLDN22

CLDN22: A Drug Target / Disease Biomarker

CLDN22 is a protein that is expressed in the endothelial cells of the body. It is a type of tight junction protein that helps to maintain the integrity of the endothelial barrier. CLDN22 has been identified as a potential drug target or biomarker for a number of diseases, including cancer, heart disease, and diabetes.

The endothelial barrier is a critical structure that separates the body's tissues from the surrounding environment. It is made up of a network of tight junction proteins that help to prevent the passage of harmful substances into the body's tissues. CLDN22 is one of these proteins, and it plays a crucial role in maintaining the integrity of the endothelial barrier.

CLDN22 is a member of the tight junction protein family, which includes a number of other proteins that help to maintain the integrity of the endothelial barrier. These proteins are called cadherins, and they are characterized by the presence of a transmembrane domain and a cytoplasmic tail. CLDN22 is unique, however, in that it has a unique N-terminus that contains a conserved region known as the N-terminal hypervariable region (HVR).

The NHR is a region of the protein that is highly variable and can differ between different species. In humans, the NHR is typically a 100 amino acid long sequence that is located at the C-terminus of the protein. It is thought to play a role in the regulation of the activity of CLDN22, as well as other proteins that are expressed in the endothelial cells of the body.

CLDN22 has been identified as a potential drug target or biomarker for a number of diseases, including cancer, heart disease, and diabetes. For example, studies have shown that CLDN22 is often expressed in various types of cancer, and that it may be a useful biomarker for monitoring the effectiveness of cancer treatments. In addition, CLDN22 has also been shown to be involved in the regulation of heart function and may be a useful target for drugs that are designed to improve heart health.

Another potential use for CLDN22 as a drug target is as a therapeutic agent for diseases that are characterized by inflammation. CLDN22 has been shown to be involved in the regulation of the immune response and may be a useful target for drugs that are designed to reduce inflammation and improve immune function.

In conclusion, CLDN22 is a protein that is expressed in the endothelial cells of the body and is thought to play a crucial role in the regulation of the endothelial barrier. It is a potential drug target or biomarker for a number of diseases, including cancer, heart disease, and diabetes. Further research is needed to fully understand the role of CLDN22 in the regulation of the endothelial barrier and its potential as a therapeutic agent.

Protein Name: Claudin 22

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets